301 related articles for article (PubMed ID: 15753394)
1. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
[TBL] [Abstract][Full Text] [Related]
2. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
[TBL] [Abstract][Full Text] [Related]
3. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
Li X; Liu YH; Zhang YP; Zhang S; Pu X; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5463-73. PubMed ID: 17875776
[TBL] [Abstract][Full Text] [Related]
4. Novel prostate-specific promoter derived from PSA and PSMA enhancers.
Lee SJ; Kim HS; Yu R; Lee K; Gardner TA; Jung C; Jeng MH; Yeung F; Cheng L; Kao C
Mol Ther; 2002 Sep; 6(3):415-21. PubMed ID: 12231179
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL.
Jiménez JA; Li X; Zhang YP; Bae KH; Mohammadi Y; Pandya P; Kao C; Gardner TA
Cancer Gene Ther; 2010 Mar; 17(3):180-91. PubMed ID: 19798123
[TBL] [Abstract][Full Text] [Related]
6. Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
Hwang JE; Joung JY; Shin SP; Choi MK; Kim JE; Kim YH; Park WS; Lee SJ; Lee KH
Cancer Lett; 2016 Mar; 372(1):57-64. PubMed ID: 26723876
[TBL] [Abstract][Full Text] [Related]
7. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.
Zeng H; Wei Q; Huang R; Chen N; Dong Q; Yang Y; Zhou Q
J Androl; 2007; 28(6):827-35. PubMed ID: 17522418
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
9. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
Zhao FJ; Zhang S; Yu ZM; Xia SJ; Li H
Prostate Cancer Prostatic Dis; 2009; 12(2):166-71. PubMed ID: 18626508
[TBL] [Abstract][Full Text] [Related]
10. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
[TBL] [Abstract][Full Text] [Related]
11. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
12. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors.
Hernandez-Alcoceba R; Pihalja M; Wicha MS; Clarke MF
Hum Gene Ther; 2000 Sep; 11(14):2009-24. PubMed ID: 11020800
[TBL] [Abstract][Full Text] [Related]
13. An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer.
Cheng WS; Dzojic H; Nilsson B; Tötterman TH; Essand M
Cancer Gene Ther; 2006 Jan; 13(1):13-20. PubMed ID: 16052227
[TBL] [Abstract][Full Text] [Related]
14. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer.
Zhao W; Xu Y; Kong D; Liu R; Zhang Z; Jin C; Zhang Z; Xiu Y
Urol Oncol; 2009; 27(5):539-47. PubMed ID: 18639471
[TBL] [Abstract][Full Text] [Related]
15. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281
[TBL] [Abstract][Full Text] [Related]
16. Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model.
Dzojic H; Cheng WS; Essand M
Cancer Gene Ther; 2007 Mar; 14(3):233-40. PubMed ID: 17053814
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter.
Li X; Zhang J; Gao H; Vieth E; Bae KH; Zhang YP; Lee SJ; Raikwar S; Gardner TA; Hutchins GD; VanderPutten D; Kao C; Jeng MH
Mol Cancer Ther; 2005 Dec; 4(12):1850-9. PubMed ID: 16373700
[TBL] [Abstract][Full Text] [Related]
18. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
Rodriguez R; Schuur ER; Lim HY; Henderson GA; Simons JW; Henderson DR
Cancer Res; 1997 Jul; 57(13):2559-63. PubMed ID: 9205053
[TBL] [Abstract][Full Text] [Related]
19. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
Yu DC; Sakamoto GT; Henderson DR
Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]